Klinische Studien

Klinische Studien

Angetrieben durch das Ziel, die Weiterentwicklung der Kardiologie voranzutreiben, führt BIOTRONIK zahlreiche klinische Studien durch.
Unsere wissenschaftlichen Aktivitäten umfassen ein weites Feld verschiedener Themengebiete wie Herzrhythmusmanagement, Elektrophysiologie und kardiovaskuläre Intervention. Dabei beschränken wir uns nicht auf den Nachweis der Sicherheit und Effizienz unserer Produkte, sondern arbeiten an den von führenden medizinischen Institutionen identifizierten Lücken in der Forschung. Bestätigt durch unsere Landmark-Studien sehen wir uns in der Verantwortung, durch aktive Beteiligung Fortschritte auf dem Gebiet der Kardiologie zu erzielen.
In Zusammenarbeit mit internationalen medizinischen Experten engagieren wir uns für die Weiterentwicklung der Diagnostik und Behandlung von kardiovaskulären Erkrankungen. Diese Kooperationen helfen uns, die Bedürfnisse der Patienten zu verstehen und ihnen die bestmögliche Behandlung zukommen zu lassen.
Die Auflistung gibt einen Überblick über laufende und abgeschlossene klinische Studien zu Herzrhythmusstörungen und kardiovaskulärer Erkrankungen und Behandlungen und bietet Verweise zu Publikationen oder anderen Quellen.

  • randomisierte klinische Studien
  • Beobachtungsstudien
  • Zulassungsstudien

Für Anfragen von medizinischen Fachkräften, die mehr über laufende klinische Studien im Bereich Kardiologie erfahren möchten, stehen wir gerne zur Verfügung.

Clinical Studies
Study Name Study Topic Study Type Number of Patients Products Therapy
CASTLE-AF Catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation Randomized controlled trial 398 Ablation catheters (any manufacturer), implantable cardioverter defibrillators, cardiac resynchronization therapy devices, BIOTRONIK Home Monitoring Cardiac rhythm management
TRUECOIN Insights from the pooled patient-level data from three randomized controlled trials utilizing daily BIOTRONIK Home Monitoring (IN-TIME, ECOST, TRUST) Meta-analysis 2405 BIOTRONIK Home Monitoring, implantable cardioverter defibrillators, cardiac resynchronization therapy devices Cardiac rhythm management
EchoCRT Effects of cardiac resynchronization therapy in heart failure with a narrow QRS complex Randomized controlled trial 1680 Cardiac resynchronization therapy devices Cardiac rhythm management
IMPACT Impact of BIOTRONIK Home Monitoring guided anticoagulation on stroke risk in patients with ICD and CRT-D devices Randomized controlled trial 2718 BIOTRONIK Home Monitoring, implantable cardioverter defibrillators, cardiac resynchronization therapy devices Cardiac rhythm management
ECOST Effectiveness and cost of ICD follow-up schedule with telecardiology Randomized controlled trial 433 BIOTRONIK Home Monitoring, implantable cardioverter defibrillators Cardiac rhythm management
MATRIX Management and detection of atrial tachyarrhythmia in patients implanted with BIOTRONIK DX systems Observational trial 2054 DX leads, implantable cardioverter defibrillators Cardiac rhythm management
IN-TIME Influence of BIOTRONIK Home Monitoring on the clinical status of heart failure patients Randomized controlled trial 664 BIOTRONIK Home Monitoring, implantable cardioverter defibrillators, cardiac resynchronization therapy devices Cardiac rhythm management
NORDIC ICD Assessment of the need of defibrillation testing Randomized controlled trial 1077 Implantable cardioverter defibrillators Cardiac rhythm management
ProMRI AFFIRM/Phase A Clinical safety of the ProMRI pacemaker system when used under specific MRI conditions with scan exclusion zone Prospective, interventional trial 272 Pacemakers Cardiac rhythm management
ProMRI Phase B Clinical safety of the ProMRI ICD system when used under specific MRI conditions without scan exclusion zone Prospective, interventional trial 170 Implantable cardioverter defibrillators Cardiac rhythm management
Protego Long-term safety and reliability of BIOTRONIK's Protego DF4 lead Observational trial 1694 Leads, implantable cardioverter defibrillators, cardiac resynchronization therapy devices Cardiac rhythm management
QP ExCELs Safety and efficacy of BIOTRONIK’s quadripolar left ventricular leads (Sentus QP) Prospective, interventional trial 1868 Leads, cardiac resynchronization therapy devices Cardiac rhythm management
REPLACE Assessment of the complication rate after cardiac device replacement Observational trial 1744 Implantable cardioverter defibrillators, cardiac resynchronization therapy devices Cardiac rhythm management
SIELLO Safety and effectiveness of the BIOTRONIK Siello S pacing lead Observational trial 1758 Leads, pacemakers Cardiac rhythm management
TRUST Efficacy and safety of automatic remote monitoring for ICD follow-up Randomized controlled trial 1450 BIOTRONIK Home Monitoring, implantable cardioverter defibrillators Cardiac rhythm management
GALAXY Long-term evaluation of the Linox family ICD leads Observational trial 1997 Leads Implantable cardioverter defibrillators Cardiac rhythm management
CELESTIAL Long-term safety and reliability of BIOTRONIK’s Corox BP LV leads Observational trial 2499 Leads, cardiac resynchronization therapy devices Cardiac rhythm management
BIOWOMEN Gender differences in the magnitude of CRT response in a heart failure population Prospective, interventional trial 494 Cardiac resynchronization therapy devices Cardiac rhythm management
BioCONTINUE Relevance of a defibrillator back-up after the replacement of the first CRT-D Observational trial 277 Implantable cardioverter defibrillators Cardiac rhythm management
BIO-RESORT Comparison of biodegradable polymer and durable polymer drug-eluting stents in an all comers population Randomized controlled trial 3530 Orsiro Drug-Eluting Stent Coronary vascular intervention
BIOSCIENCE Orsiro Sirolimus-eluting stent with biodegradable polymer vs Xience Prima everolimus-eluting stent Randomized controlled trial 2100 Orsiro Drug-Eluting Stent Coronary vascular intervention
SORT-OUT VII BIOTRONIK Sirolimus-eluting Orsiro stent vs Terumo biolimus-eluting Nobori Stent Randomized controlled trial 2525 Orsiro Drug-Eluting Stent Coronary vascular intervention
ORIENT Comparison of the angiographic result of the Orsiro stent with Resolute Integrity stent Randomized controlled trial 375 Orsiro Drug-Eluting Stent Coronary vascular intervention
SCAAR Swedish Coronary Angiography and Angioplasty Registry Observational trial > 270000 Orsiro Drug-Eluting Stent Coronary vascular intervention
BIOFLOW-I First-in-man experience with a drug-eluting stent in de novo coronary artery lesions First-in-man trial 30 Orsiro Drug-Eluting Stent Coronary vascular intervention
BIOFLOW-II Study of the Orsiro Drug Eluting Stent System Randomized controlled trial 440 Orsiro Drug-Eluting Stent Coronary vascular intervention
BIOFLOW-III Investigating Orsiro drug-eluting coronary stent Observational trial 1356 Orsiro Drug-Eluting Stent Coronary vascular intervention
BIOFLOW-V Randomized Clinical Trial Comparing Orsiro1 Drug-Eluting Stent with Xience2 DES Randomized controlled trial 1334 Orsiro Drug-Eluting Stent Coronary vascular intervention
BIOSOLVE-I First-in man trial with DREAMS (Drug-Eluting Absorbable Magnesium Scaffold) First-in-man trial 46 Magmaris Resorbable Magnesium Scaffold Coronary vascular intervention
BIOSOLVE-II First in man study of the DREAMS 2nd generation drug-eluting absorbable metal scaffold First-in-man trial 123 Magmaris Resorbable Magnesium Scaffold Coronary vascular intervention
DELUX Drug-Releasing Pantera Lux PTCA Balloon Catheter Registry Observational trial 1064 Pantera Lux Paclitaxel-Releasing Balloon Coronary vascular intervention
ENERGY Registry to evaluate the clinical performance of the PRO-Kinetic Energy BMS in a large real-world patient population. Observational trial 1016 PRO-Kinetic Energy Cobalt Chromium Stent Coronary vascular intervention
ISAR-DESIRE 4 Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug-Eluting Stent In-Stent Restenosis 4 Randomized controlled trial 252 Pantera Lux Paclitaxel-Releasing Balloon, AngioSculpt Scoring Balloon Coronary vascular intervention
PEBSI A Randomized Trial of Paclitaxel-Eluting Balloon after Bare Metal Stent Implantation versus Bare Metal Stent in ST Elevation Myocardial Infarction (STEMI) Randomized controlled trial 223 PRO-Kinetic Energy Stent, Pantera Lux Paclitaxel-Releasing Balloon Coronary vascular intervention
PEPPER First-In-Human Trial - Paclitaxel-Releasing Balloon in Patients Presenting with In-Stent Restenosis Observational trial 81 Pantera Lux Paclitaxel-Releasing Balloon Coronary vascular intervention
4EVER Physician-initiated trial investigating the safety of the full 4F endovascular treatment approach of infra-inguinal arterial stenotic disease Observational trial 120 Astron Pulsar, Pulsar-18 Self-Expanding Stents Peripheral vascular intervention
BERN Evaluate long segment (> 120 mm) complex femoro-popliteal disease with Pulsar stent stratified for Critical Limb Ischaemia vs. Intermittent Claudication1 Observational trial 31 Pulsar-18 Self-Expanding Stent Peripheral vascular intervention
BIOFLEX-I Prospective, international, multi-center, investigational device exemption trial evaluating BIOTRONIK Astron nitinol self-expanding stent for iliac arteries Observational trial 161 Astron Self-Expanding Stent Peripheral vascular intervention
BIOLUX P-I Clinical trial to assess the safety and performance of the coated Passeo-18 Lux paclitaxel-releasing PTA balloon catheter versus the uncoated Passeo-18 balloon catheter for treatment of stenosis of the femoropopliteal arteries Randomized controlled trial 60 Passeo-18 Lux Drug-Coated Balloon, Passeo-18 PTA Balloon Peripheral vascular intervention
BIOLUX P-II First-in-human study to assess the safety and performance of the Passeo-18 Lux drug-coated balloon vs. the uncoated Passeo-18 balloon catheter in patients with stenosis and occlusion of the infrapopliteal arteries Randomized controlled trial 72 Passeo-18 Lux Drug-Coated Balloon, Passeo-18 PTA Balloon Peripheral vascular intervention
DEBAS To evaluate the outcome of the implantation of the Pulsar-18 stent followed by Passeo-18 Lux drug-coated balloon in the femoropopliteal arteries Observational trial 65 Pulsar-18 Self-Expanding Stent, Passeo-18 Lux Drug-Coated Balloon Peripheral vascular intervention
PEACE Pulsar efficacy - An all-comers registry: 12-month results 1 Observational trial 148 Pulsar-18 Self-Expanding Stent Peripheral vascular intervention
TASC D Twelve months effectiveness analysis of the Pulsar-18 self-expanding nitinol stent in patients with critical limb ischemia1 Observational trial 22 Pulsar-18 Self-Expanding Stent Peripheral vascular intervention
TASC D II Evaluation of the 4 French Pulsar-18 self-expanding nitinol stent in long femoropopliteal lesions (TASC D II) – 12-month results Observational trial 36 Pulsar-18 Self-Expanding Stent Peripheral vascular intervention